Oxyrane UK Limited is a biopharmaceutical company dedicated to the development of novel and biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. Founded in 2006, the Company is headquartered in Manchester, United Kingdom with research facilities in Ghent, Belgium.

Financials